New insights on attention-deficit/hyperactivity disorder pharmacogenomics

Drug Development Research

Volumn 62, Issue 3, 2004, Pages 172-179

  Rohde, Luis Augusto ^a,b   Zeni, Cristian ^a   Polanczyk, Guilherme ^a   Hutz, Mara H ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

ADHD; Dopamine transporter gene; Pharmacogenetics; Pharmacogenomics

Indexed keywords

ATOMOXETINE; CENTRAL STIMULANT AGENT; METHYLPHENIDATE;

ALLELE; ATTENTION DEFICIT DISORDER; CLINICAL TRIAL; DAT1 GENE; DOCUMENTATION; DOPAMINERGIC GENE; GENE; GENE INTERACTION; GENETIC POLYMORPHISM; GENETICS; HOMOZYGOSITY; HUMAN; MEDICAL LITERATURE; META ANALYSIS; PHARMACOGENOMICS; PUBLICATION; REVIEW; SYSTEMATIC REVIEW;

EID: 10044248358     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/ddr.10380     Document Type: Review

References (52)

1. American Academy of Pediatrics. 2001. Clinical practice guideline: treatment of school age children with ADHD. Pediatrics 108:1033-1044.
2. American Psychiatric Association. 1994. Diagnostic and statistical manual of mental disorders, fourth edition. Washington, DC: American Psychiatric Association, p 78-85.
3. Barkley RA. 1997. Behavioral inhibition, sustained attention, and executive functions: constructing a unifying theory of ADHD. Psychol Bull 121:65-94.
4. Barr CL, Wigg K, Malone M, Schachar R, Tannock R, Roberts W, Kennedy JL. 1999. Linkage study of catechol-O-methyltransferase and attention-deficit hyperactivity disorder. Am J Med Genet 88:710-713.
5. Biederman J, Spencer T. 1999. Attention-deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder. Biol Psychiatry 46:1234-1242.
6. Castellanos FX. 1997. Toward a pathophysiology of attention-deficit/ hyperactivity disorder. Clin Pediatr 36:381-393.
7. Castellanos FX, Tannock R. 2002. Neuroscience of attention-deficit/ hyperactivity disorder: the search for endophenotypes. Nat Rev Neurosci 3:617-628.
8. Daly G, Hawi Z, Fitzgerald M, Gill M. 1999. Mapping susceptibility loci in attention-deficit/hyperactivity disorder: preferential transmission of parental alleles at DAT1, DBH and DRD5 to affected children. Mol Psychiatry 4:192-196.
9. Eisenberg J, Mei-Tal G, Steinbeg A, Tartakovsky E, Zohar A, Gritsenko I, Nemanov L, Ebstein RP. 1999. Haplotype relative risk study of catechol-O-methyltrausferase (COMT) and attention-deficit/hyperactivity disorder (ADHD): association of the high-enzyme activity Val allele with ADHD impulsive-hyperactive phenotype. Am J Med Genet 88:497-502.
10. Faraone SV, 2000a. Genetics of childhood disorders: XX. ADHD, part 4: is ADHD genetically heterogeneous? J Am Acad Child Adolesc Psychiatry 39:1455-1457.
11. Faraone SV, Biederman J, Monuteaux MC. 2000b. Toward guidelines for pedigree selection in genetic studies of attention-deficit/hyperactivity disorder. Genet Epidemiol 18:1-16.
12. Faraone SV, Doyle AE, Mick E, Biederman J. 2001. Meta-analysis of the association between the dopamine D4 gene 7-repeated allele and attention-deficit/hyperactive disorder. Am J Psychiatry 158:1052-1057.
13. Faraone SV, Sergeant J, Gillberg C, Biederman J. 2003. The worldwide prevalence of ADHD: is it an American condition? World Psychiatry 2:104-113.
14. Faraone SV, Spencer T, Aleardi M, Pagano C, Biederman J. 2004. Meta-analysis of the efficacy of methylphenidate for treating adult attention deficit/hyperactivity disorder. J Clin Psychopharmacol 24:24-29.
15. Fuke S, Suo S, Takahashi N, Koike H, Sasagawa N, Ishiura S. 2001. The VNTR polymorphism of the human dopamine transporter (DAT1) gene affects gene expression. Pharmacogenomics J 1:152-156.
16. Hamarman S. 2002. ADHD children with DRD4 7-repeat allele require higher stimulant doses. Presented in the 49th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, San Francisco, October 2002.
17. Hamarman S, Ulger C, Fossella J, Brimacombe M, Dermody J. 2003. Influence of dopamine genes on stimulant response in ADHD children. Presented in the 50th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Miami, October 2003.
18. Heinz A, Goldman D, Jones DW, Palmour R, Hommer D, Gorey JG, Lee KS, Linnoila M, Weinberger DR. 2000. Genotype influences in vivo dopamine transporter availability in human striatum. Neuropsychopharmacology 22:133-139.
19. Kent L, Doerry U, Hardy E, Parmar R, Gingell K, Hawl Z, Kirley A, Lowe N, Fitzgerald M, Gill M, Craddock N. 2002. Evidence that variation at the serotonin transporter gene influences susceptibility to attention deficit hyperactivity disorder (ADHD): analysis and pooled analysis. Mol Psychiatry 7:908-912.
20. Kirley A, Lowe N, Hawi Z, Mullins C, Daly G, Waldman I, McCarro M, O'Donnel D, Fitzgerald M, Gill M. 2003. Association of the 480 bp DAT1 allele with methylphenidate response in a sample of Irish children with ADHD. Am J Med Genet 121B: 50-54.
21. Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski CL, Weinshilboum RM. 1996. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 6:243-250.
22. Lichter JB, Barr CL, Kennedy JL, Van Tol HHM, Kickl KK, Livak KJ. 1993. A hypervariable segment in the human dopamine receptor D4 (DRD4) gene. Hum Mol Genet 2:767-773.
23. Loo SK, Specter E, Smolen A, Hopler C, Teale PD, Reite ML. 2003. Functional Effects of the DAT1 Polymorphism on EEG Measures in ADHD. J Am Acad Child Adolesc Psychiatry 42: 986-993.
24. Masellis M, Basile VS, Muglia P, Ozdemir V, Macciardi FM, Kennedy JL. 2002. Psychiatric pharmacogenetics: personalizing psychostimulant therapy in attention deficit/hyperactivity disorder. Behav Brain Res 130:85-90.
25. 158-met genotype and individual variation in the brain response to amphetamine. Proc Natl Acad Sci USA 100:6186-6191.
26. Michelson D, Adler L, Spencer T, Reimherr FW, West SA, Allen AJ, Kelsey D, Wernicke J, Dietrich A, Milton D. 2003. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry 53:112-120.
27. Mill J, Asherson P, Browes C, D'Souza U, Craig I. 2002. Expression of the dopamine transporter gene is regulated by the 3′ UTR VNTR: evidence from brain and lymphocytes using quantitative RT-PCR. Am J Med Genet (Neuropsychiatr Genet) 114:975-979.
28. Ogdie MN, Macphie IL, Yang M, Fisher SE, Francks C, Cantor RM, McCracken JT, McGough JJ, Nelson Monaco AP, Smalley SL. 2003. A genomewide scan for attention-deficit/hyperactivity disorder in an extended sample: suggestive linkage on 17p11. Am J Hum Genet 72:1268-1279.
29. Payton A, Holmes J, Barrett JH, Hever T, Fitzpatrick H, Trumper AL, Harrington R, McGuffin P, O'Donovan M, Owen M, Ollier W, Worthington J, Thapar A. 2001. Examining for association between candidate gene polymorphisms in the dopamine pathway and attention-deficit /hyperactivity disorder: a family-based study. Am J Med Genet 105:464-470.
30. Pliszka SR, McCracken JT, Maas JW. 1996. Catecholamines in attention-deficit/hyperactivity disorder: current perspectives. J Am Acad Child Adolesc Psychiatry 35:264-272.
31. Rohde LA, Biederman J, Busnello EA, Zimmermann H, Schmitz M, Martins S, Tramontina S. 1999. ADHD in a school sample of Brazilian adolescents: a study of prevalence, comorbid conditions and impairments. J Am Acad Child Adolesc Psychiatry 38:716-722.
32. Rohde LA, Roman T, Hutz M. 2003a. Attention-deficit/hyperactivity disorder: current aspects on pharmacogenetics. J Pharmacogenomics 3:11-13.
33. Rohde LA, Roman T, Szobot C, Cunha RD, Biederman J, Hutz MH. 2003b. Dopamine transporter gene, response to methylphenidate and cerebral blood flow in ADHD. Synapse 48:87-89.
34. Roman T, Schmitz M, Polanczyk G, Eizirik M, Rohde LA, Hutz M. 2001. Attention-deficit/hyperactivity disorder: a study of association with both DAT and DRD4 genes. Am J Med Genet 105: 471-478.
35. Roman T, Schmitz M, Polanczyk G, Eizirik M, Rohde LA, Hutz M. 2002a. Further evidence for the association between DBH gene and attention-deficit/ hyperactivity disorder. Am J Med Genet 114:154-158.
36. Roman T, Szobot C, Martins S, Biederman J, Rohde LA, Hutz MH. 2002b. Dopamine transporter gene and response to methylphenidate in attention-deficit/hyperactivity disorder. Pharmacogenetics 12:497-499.
37. Roman T, Schmitz M, Polanczyk G, Eizirik M, Rohde LA, Hutz M. 2003. Association between α-2a adrenergic receptor gene (adra2a) and attention-deficit/hyperactivity disorder. Am J Med Gen (Neuropsychiatr Genet) 120B:116-120.
38. Roman T, Rohde LA, Hutz M. 2004. Polymorphisms of the dopamine transporter gene: influence on response to methylphenidate in attention-deficit/hyperactivity. Am J Pharmacogenomic 4:83-92.
39. Russell V, Allie S, Wiggins T. 2000. Increased noradrenergic activity in prefrontal cortex slices of an animal model for attention-deficit hyperactivity disorder-the spontaneously hypertensive rat. Behav Brain Res 117:69-74.
40. Seeger G, Schloss P, Schmidt MH. 2001. Marker gene polymorphisms in hyperkinetic disorder-predictors of clinical response to treatment with methylphenidate? Neurosci Lett 313:45-48.
41. Smalley SL. 1997. Genetic influences in childhood-onset psychiatric disorders: autism and attention-deficit/hyperactivity disorder. Am J Hum Genet 60:1276-1282.
42. Spencer T, Heiligenstein J, Biederman J, Faries D, Kratochvil C, Conners CK, Potter WZ. 2002. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 63:1140-1147.
43. Stein MA, Sarampote C, Waldman I, Seymour K, Robb A, Conlon C, Yang Z, Cook E. 2002. Dopamine transporter genotype affects stimulants response according to parent ratings. Presented in the 49th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, San Francisco, October 2002.
44. Swanson JM, Flodman P, Kennedy J, Spence MA, Moyzis R, Schuck S, Murias M, Moriarity J, Barr C, Smith M, Posner M. 2000. Dopamine genes and ADHD. Neurosci Biobehav Rev 24:21-25.
45. Szobot C, Roman T, Cunha R, Acton P, Rohde LA, Hutz M (in press). Brain perfusion and dopaminergic genes in boys with ADHD. Am J Med Genet.
46. Tahir E, Yazgan Y, Cirakoglu B, Ozbay F, Waldman I, Asherson PJ. 2000. Association and linkage of DRD4 and DRD5 with attention deficit hyperactivity disorder (ADHD) in a sample of Turkish children. Mol Psychiatry 5:396-404.
47. Tribut O, Lessard Y, Reymann JM, Allain H, Bentué-Ferrer D. 2002. Pharmacogenomics. Med Sci Monit 8:RA 152-163.
48. Volkow ND, Wang GJ, Fowler JS, Logan J, Franceschi D, Maynard L, Ding YS, Gatley SJ, Gifford A, Zhu W, Swanson JM. 2002. Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: therapeutic implications. Synapse 43:181-187.
49. Volkow ND, Fowler JS, Wang G, Ding Y, Gattley SJ. 2002. Mechanism of action of methylphenidate: Insights from PET imaging studies. J Attention Disord 6:S-31-43.
50. Winsberg BG, Comings DE. 1999. Association of the Dopamine Transporter Gene (DAT1) with poor methylphenidate response. J Am Acad Child Adolesc Psychiatry 38:1474-1477.
51. Yang L, Wang Y, Li J, Faraone S. (in press). Association of norepinephrine transporter gene (NET) with methylphenidate response. J Am Acad Child Adolesc Psychiatry 9:1154-1158.
52. Yeh M, Morley KI, Hall WD. 2004. The policy and ethical implications of genetic research on attention deficit hyperactivity disorder. Aust N Z J Psychiatry 38:10-19.